At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 10, 2026 at 16:35 ET
Kura Oncology is holding its annual shareholder meeting to vote on director elections, auditor appointment, executive compensation, and equity plan amendments. This is a routine filing with no material financial impact.
- Kura Oncology is holding its annual shareholder meeting on June 4, 2026
- Shareholders will vote on the election of three Class III directors
- The board recommends ratification of Ernst & Young as independent auditors
- The board recommends approval of executive compensation (Say-on-Pay)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access